Dexcom Posts Strong Q1 2026 Growth on CGM Demand
Event summary
- Revenue grew 15% YoY to $1.192B on a reported basis, with international revenue up 26%.
- GAAP operating income increased by 850 basis points to $255.3M (21.4% of revenue).
- Dexcom expanded the launch of Dexcom G7 15 Day CGM across all U.S. channels.
- Introduced enhanced Smart Meal Logging features to the Stelo platform.
- Raised fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin.
The big picture
Dexcom's strong Q1 2026 results reflect robust demand for its continuous glucose monitoring (CGM) systems, particularly internationally. The company's focus on operational improvements and product innovation positions it well in the competitive diabetes management market. With raised guidance for operating margins, Dexcom is signaling confidence in its ability to balance growth with profitability.
What we're watching
- Market Expansion
- Whether Dexcom can sustain its 26% international revenue growth amid foreign exchange volatility.
- Operational Efficiency
- The pace at which Dexcom improves margins while expanding production capacity and exploring new markets.
- Product Innovation
- How the enhanced Smart Meal Logging features on the Stelo platform will impact user engagement and retention.
Related topics